Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity

An update from Aethlon Medical ( (AEMD) ) is now available.

Aethlon Medical, Inc., a medical technology company, reported that it has 1,569,110 shares of common stock outstanding as of the close of business on March 16, 2026, following recent exercises of certain pre-funded warrants. The company confirmed that all previously outstanding pre-funded warrants have now been exercised, simplifying its capital structure and consolidating investor positions into common equity.

This development may streamline Aethlon Medical’s equity base by eliminating a class of derivative securities tied to its stock. It can also provide greater transparency for shareholders and potential investors regarding the company’s fully diluted share count and current ownership structure.

The most recent analyst rating on (AEMD) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aethlon Medical stock, see the AEMD Stock Forecast page.

Spark’s Take on AEMD Stock

According to Spark, TipRanks’ AI Analyst, AEMD is a Neutral.

The score is primarily weighed down by very weak financial performance (persistent losses and cash burn) and a bearish technical setup (below key moving averages with negative MACD). Offsetting factors include constructive clinical progress and cost discipline discussed on the earnings call, but limited cash runway and dilution-related corporate actions temper the upside.

To see Spark’s full report on AEMD stock, click here.

More about Aethlon Medical

Aethlon Medical, Inc. is a medical technology company operating in the healthcare sector. It focuses on developing and commercializing therapeutic devices and related solutions, with its activities centered on issuing and managing common stock as part of its corporate financing structure.

Average Trading Volume: 64,166

Technical Sentiment Signal: Strong Sell

Current Market Cap: $2.77M

Find detailed analytics on AEMD stock on TipRanks’ Stock Analysis page.